Every Monday (or Tuesday… #labordayweekend) we share a quick “best of” from the week that was with our Inner Circle members. What’s trending in the Femtech Insider community and beyond? We’ve got you covered! In this week’s brief we talk about…

  • Spotlight: Endometriosis Diagnostics and Care
  • Investment Round-up: August 2022
  • Startup Spotlight: 3 Daughters, Khyria & Vital Startup Health
  • And more!

Spotlight: Endometriosis – Diagnostics & Care

It’s been a busy couple of weeks when it comes to news from the world of endometriosis diagnostics and care. Busy enough that it can get hard to keep track of all the developments and annoucnements. So today we thought we’d share a bit of a round-up of recent news and discoveries, that we thought you’d be particularly interested in!

But before we kick off, let’s spend a moment to talk about what endometriosis actually is and how it is diagnosed. 👇

➡️ Endometriosis 101

Just like many other conditions in the women’s health space endometriosis is under researched, underserved and underfunded although it affects around 170 million women globally (1 in 10). The most common symptom of endometriosis is pelvic pain, which often correlates to the menstrual cycle.

The majority of women with endometriosis also report comorbidities such as migraine, depression, anxiety, IBS, chronic fatigue, fibromyalgia, uterine fibroids, and ovarian cysts. 

Women with endometriosis are at slightly higher risk for several types of cancer (e.g. ovarian cancer), systemic lupus, rheumatoid arthritis and cardiovascular disease.

🤔 How Is Endometriosis Diagnosed?

As the symptoms of the disease are not easily recognized as endometriosis – by providers and affected women – many experience a significant diagnostic delay. There is no simple test to diagnose endometriosis, the gold standard is currently a laparoscopy.

The diagnostic pathway is complex and inefficient, and unfortunately treatment options currently available for women living with endometriosis are limited as well. The causes of disease are unknown and there currently is no cure. To alleviate symptoms women are usually either given hormonal treatment or may have to undergo complex surgery. 

🤔 The Impact

Endometriosis places a significant economic and social burden on patients, their families, and society as it affects most aspects of a patient’s daily life, including sexual wellness, physical wellbeing (nutrition, sleep, fitness), emotional wellbeing, social life, child care and the ability to have children.

It is estimated that total workplace productivity loss averages 6.3 hours per week (absenteeism), while household productivity loss averages 4.9 hours per week.

🚀 What’s New?

Femtech company AIMA has teamed up with Innovative Health Diagnostics to develop a new at-home test for endometriosis. The new test identifies certain microRNA biomarkers that are differentially expressed in women with endometriosis compared to women without.

Hera Biotech has raised $1.9M in seed funding for its non-surgical diagnostic test for endometriosis. The new funding will support the commercialization of MetriDx.

DotLab was granted patents for DotEndo, its non-invasive endometriosis test. Via its clinical studies, DotLab has pioneered medical tests enabled by single-stranded, non-coding RNAs called microRNAs in circulating body fluids such as blood and saliva.

Myovant Sciences and Pfizer have received FDA approval for MYFEMBREE, a once-daily endometriosis treatment. The one-pill, once-a-day therapy will help the management moderate to severe pain associated with endometriosis in pre-menopausal women, with a treatment duration of up to 24 months.Women’s Health Innovation Summit recently announced the finalists of this year’s pitch competition and we spotted a two companies focused on endometriosis among them as well:

Welcome! You\’ve found some of our exclusive Inner Circle Content. 

This article is only available for our Inner Circle Members. To read on: